Handelsbanken Fonder AB reduced its stake in Vertex Pharmaceuticals by 28.1% in Q4, selling 115,479 shares. The fund now owns ...
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a ...
Shares of bluebird bio (NASDAQ:BLUE) continued their downward descent Monday in the wake of news that the company has been agreed to be taken private by Carlyle Group (NASDAQ:CG) and SK Capital ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $407.00 to $408.00 ...
Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Vertex Pharmaceuticals in a research note issued to ...
Hosted on MSN4d
GILD or VRTX: Which Is the Better Value Stock Right Now?Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two ...
The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback